(Q45875250)

17 December 2017

title

Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors (English)

1 reference

17 December 2017

0 references

1 reference

W K Hoots

1

1 reference

17 December 2017

L S Ebbesen

2

1 reference

17 December 2017

B A Konkle

3

1 reference

17 December 2017

G K-H Auerswald

4

1 reference

17 December 2017

H R Roberts

5

1 reference

17 December 2017

J Weatherall

6

1 reference

17 December 2017

J-M Ferran

7

1 reference

17 December 2017

R C R Ljung

8

1 reference

17 December 2017

Novoseven (F7HAEM-1505) Investigators

9

1 reference

17 December 2017

publication date

12 February 2008

1 reference

17 December 2017

published in

Haemophilia

1 reference

17 December 2017

volume

14

1 reference

17 December 2017

issue

3

1 reference

17 December 2017

page(s)

466-475

1 reference

17 December 2017

Inhibitors: resolving diagnostic and therapeutic dilemmas

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01654.X

Pathogenesis of haemophilic arthropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01654.X

Pain and functional limitations in patients with severe haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01654.X

Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01654.X

European study on orthopaedic status of haemophilia patients with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01654.X

Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01654.X

Haemophilia prophylaxis in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01654.X

Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01654.X

Resource utilisation in haemophiliacs treated in Europe: results from the European Study on Socioeconomic Aspects of Haemophilia Care. The European Socioeconomic Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01654.X

Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01654.X

Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01654.X

Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01654.X

Prophylactic treatment with FEIBA of a haemophilia A patient with inhibitor: what are the costs, what are the benefits?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01654.X

Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01654.X

Measuring health state preferences for hemophilia: development of a disease-specific utility instrument

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01654.X

Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01654.X

Cost-utility analysis of recombinant factor VIIa (NovoSeven) in six children with long-standing inhibitors to factor VIII or IX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01654.X

Assessing health-related quality-of-life in individuals with haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01654.X

Impact of recombinant activated factor VII on health-related quality of life after intracerebral hemorrhage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01654.X

Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01654.X

Cost-utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01654.X

10.1111/J.1365-2516.2008.01654.X

21 January 2018

Identifiers

DOI

1 reference

17 December 2017

1 reference

17 December 2017